Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Multimedia
Multimedia Library
Orphan Drugs - A flattening curve?
Are orphan drugs approaching their peak? View our market snapshot
2023 Preview
Biotech and pharma: from bad to worse, or better in 2023? Amy Brown and Edwin Elmhirst from Evaluate Vantage, discuss what the coming year is likely to bring.
Illiquid Gold: Creative Dealmaking in Biotech
Evaluate and Treehill Partners discuss the state of play and look for smart ways to get investment and deals moving as we head into 2023.
World Preview to 2028: Patents and Pricing
View the webinar: Don't miss our pharma and biotech outlook to 2028.
The Billion Dollar Question: Are payer perspectives part of your strategy?
Webinar video now available to watch on-demand
Tricky Terrain: Navigating the Pharma Investment Landscape
2022 got off to an uncertain start for the biopharma industry.
Biopharma 2022: What's Next?
After getting off to a pretty dismal start, what does the rest of the year hold for the biopharma market?